TARGET ONCOL 润色咨询

Targeted Oncology

出版年份：2006 年文章数：444 投稿命中率： 开通期刊会员，数据随心看

出版周期：Quarterly 自引率：1.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2026-04-18 ms9000001489573181 来自河南省

    审稿速度:12.0 | 投稿命中率:5.0
    经验分享：不是约稿非常慢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2022-09-09 ms5000000784770068

    这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2022-06-08 ms6000000109847069

    偏重的研究方向：综述
    经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2022-06-08 ms6000000109847069

    偏重的研究方向：癌症;综述
    经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2018-10-06 灬赫梦灬

    审稿速度:1.0
    经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2021-03-16 ms5000000299297974

    请问有人投吗？为什么我提交文稿好几天了还是New Submission

    10

    展开10条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2022-03-25 12133f96m16(暂无昵称)

    要原始数据？

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2021-12-28 Mia

    摘要中一定要加入研究目标么？

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2021-12-27 桑晒麦拉

    摘要撰写有什么套路？有没有模板？

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2307964, encodeId=887b230e964ab, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：不是约稿非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7da9974030, createdName=ms9000001489573181, createdTime=Sat Apr 18 08:45:46 CST 2026, time=2026-04-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述<br>经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述<br>经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0<br>经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-20 12433748m86(暂无昵称)

    TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？

    0

共32条页码: 1/4页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分